行情

XNCR

XNCR

Xencor
NASDAQ

实时行情|Nasdaq Last Sale

32.19
-1.16
-3.48%
盘后: 32.74 +0.55 +1.72% 16:11 02/27 EST
开盘
32.85
昨收
33.35
最高
33.65
最低
31.70
成交量
40.99万
成交额
--
52周最高
46.33
52周最低
27.75
市值
18.33亿
市盈率(TTM)
72.96
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测XNCR价格均价为45.55,最高价位56.00,最低价为21.00。

EPS

XNCR 新闻

更多
  • How Should Investors Feel About Xencor, Inc.'s (NASDAQ:XNCR) CEO Pay?
  • Simply Wall St. · 1天前
  • Guggenheim Securities Upgrades Xencor to Buy, Announces $43 Price Target
  • Benzinga · 2天前
  • Edited Transcript of XNCR earnings conference call or presentation 24-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 2天前
  • Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2019 - Earnings Call Transcript
  • Seeking Alpha - Transcript · 2天前

所属板块

生物技术和医学研究
-2.78%
制药与医学研究
-2.83%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

XNCR 简况

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
展开

微牛提供Xencor Inc(NASDAQ-XNCR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的XNCR股票新闻,以帮助您做出投资决策。